Avalyn Pharma Files for US Initial Public Offering to Develop Inhaled Respiratory Treatments

U.S. Securities and Exchange Commission on October 10, 2024, for an initial public offering of its common stock. The company is headquartered in Seattle, Washington, and was founded in 2018. It focuses on creating targeted inhaled therapies to treat serious lung conditions, including idiopathic pulmonary fibrosis, sarcoidosis, and other interstitial lung diseases.

The proposed IPO involves offering shares through an underwritten public offering, with the number of shares and price range to be determined later. Proceeds from the offering would support research and development of Avalyn's product candidates, clinical trials, manufacturing scale-up, and general corporate purposes.

Avalyn's lead candidate, AP01, is an inhaled formulation of pirfenidone currently in Phase 2 trials for idiopathic pulmonary fibrosis.

Pharma has developed a proprietary dry powder aerosol platform to deliver drugs directly to the lungs, aiming to improve efficacy and reduce systemic side effects compared to oral or intravenous administration.

The company's pipeline includes additional candidates like AP02, an inhaled formulation of nintedanib for progressive pulmonary fibrosis, which is in preclinical stages. Prior to the IPO filing, Avalyn raised approximately $200 million in private funding rounds from investors such as ARCH Venture Partners, Bristol Myers Squibb, and SV Health Investors.

Respiratory diseases affect millions worldwide, with idiopathic pulmonary fibrosis alone impacting about 50,000 people in the United States.

Avalyn's therapies target unmet needs in these areas, where current treatments often have limited effectiveness or significant tolerability issues. 6 million for the year ended December 31, 2023.

The IPO filing comes amid a recovering market for biotech listings, following a slowdown in 2022-2023 due to high interest rates and investor caution.

" BofA Securities, Jefferies, and Guggenheim Securities are acting as lead book-running managers for the proposed offering. U.S. Securities and Exchange Commission must review and declare the registration statement effective before any shares can be sold.

Avalyn plans to use the funds to advance its clinical programs toward potential regulatory approvals, which could take several years. Investors, patients with respiratory conditions, and the biotech sector are among those affected by the outcome of this filing.